Literature DB >> 27341789

Estimating the effect of endogenous dopamine on baseline [(11) C]-(+)-PHNO binding in the human brain.

Fernando Caravaggio1,2, Lawrence S Kegeles3, Alan A Wilson1,2,4, Gary Remington1,2,4, Carol Borlido1, David C Mamo5, Ariel Graff-Guerrero6,7,8.   

Abstract

Endogenous dopamine (DA) levels at dopamine D2/3 receptors (D2/3 R) have been quantified in the living human brain using the agonist radiotracer [(11) C]-(+)-PHNO. As an agonist radiotracer, [(11) C]-(+)-PHNO is more sensitive to endogenous DA levels than antagonist radiotracers. We sought to determine the proportion of the variance in baseline [(11) C]-(+)-PHNO binding to D2/3 Rs which can be accounted for by variation in endogenous DA levels. This was done by computing the Pearson's coefficient for the correlation between baseline binding potential (BPND ) and the change in BPND after acute DA depletion, using previously published data. All correlations were inverse, and the proportion of the variance in baseline [(11) C]-(+)-PHNO BPND that can be accounted for by variation in endogenous DA levels across the striatal subregions ranged from 42-59%. These results indicate that lower baseline values of [(11) C]-(+)-PHNO BPND reflect greater stimulation by endogenous DA. To further validate this interpretation, we sought to examine whether these data could be used to estimate the dissociation constant (Kd) of DA at D2/3 R. In line with previous in vitro work, we estimated the in vivo Kd of DA to be around 20 nM. In summary, the agonist radiotracer [(11) C]-(+)-PHNO can detect the impact of endogenous DA levels at D2/3 R in the living human brain from a single baseline scan, and may be more sensitive to this impact than other commonly employed radiotracers.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  AMPT; D2/3R; PET; [11C]-(+)-PHNO; dopamine

Mesh:

Substances:

Year:  2016        PMID: 27341789      PMCID: PMC5328677          DOI: 10.1002/syn.21920

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  71 in total

1.  Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at Ultra High Risk for psychosis.

Authors:  Oswald J N Bloemen; Mariken B de Koning; Tobias Gleich; Julia Meijer; Lieuwe de Haan; Don H Linszen; Jan Booij; Thérèse A M J van Amelsvoort
Journal:  Eur Neuropsychopharmacol       Date:  2012-05-14       Impact factor: 4.600

2.  Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study.

Authors:  Jeffrey H Meyer; Heather E McNeely; Sandra Sagrati; Anahita Boovariwala; Krystle Martin; N Paul L G Verhoeff; Alan A Wilson; Sylvain Houle
Journal:  Am J Psychiatry       Date:  2006-09       Impact factor: 18.112

Review 3.  Extrasynaptic release of GABA and dopamine by retinal dopaminergic neurons.

Authors:  Hajime Hirasawa; Massimo Contini; Elio Raviola
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-07-05       Impact factor: 6.237

4.  Quantitative imaging of protein targets in the human brain with PET.

Authors:  Roger N Gunn; Mark Slifstein; Graham E Searle; Julie C Price
Journal:  Phys Med Biol       Date:  2015-10-29       Impact factor: 3.609

5.  Dopaminergic dendrites in the pars reticulata of the rat substantia nigra and their striatal input. Combined immunocytochemical localization of tyrosine hydroxylase and anterograde degeneration.

Authors:  M Wassef; A Berod; C Sotelo
Journal:  Neuroscience       Date:  1981       Impact factor: 3.590

6.  Interactions of agonists with D-2 dopamine receptors: evidence for a single receptor population existing in multiple agonist affinity-states in rat striatal membranes.

Authors:  M W Hamblin; S E Leff; I Creese
Journal:  Biochem Pharmacol       Date:  1984-03-15       Impact factor: 5.858

7.  Effect of dopamine receptor agonists and antagonists on release of dopamine in the rabbit caudate nucleus in vitro.

Authors:  K Starke; W Reimann; A Zumstein; G Hertting
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-10       Impact factor: 3.000

8.  Test-retest reproducibility of [11C]-(+)-propyl-hexahydro-naphtho-oxazin positron emission tomography using the bolus plus constant infusion paradigm.

Authors:  Dianne E Lee; Jean-Dominique Gallezot; Ming-Qiang Zheng; Keunpoong Lim; Yu-Shin Ding; Yiyun Huang; Richard E Carson; Evan D Morris; Kelly P Cosgrove
Journal:  Mol Imaging       Date:  2013 Mar-Apr       Impact factor: 4.488

9.  Small effect of dopamine release and no effect of dopamine depletion on [18F]fallypride binding in healthy humans.

Authors:  Vanessa L Cropley; Robert B Innis; Pradeep J Nathan; Amira K Brown; Janet L Sangare; Alicja Lerner; Yong Hoon Ryu; Kelly E Sprague; Victor W Pike; Masahiro Fujita
Journal:  Synapse       Date:  2008-06       Impact factor: 2.562

10.  Estimation of baseline dopamine D2 receptor occupancy in striatum and extrastriatal regions in humans with positron emission tomography with [18F] fallypride.

Authors:  Patrizia Riccardi; Ron Baldwin; Ronald Salomon; Sharlet Anderson; Mohammad S Ansari; Rui Li; Benoit Dawant; Amy Bauernfeind; Dennis Schmidt; Robert Kessler
Journal:  Biol Psychiatry       Date:  2007-06-27       Impact factor: 13.382

View more
  7 in total

1.  The relationship between subcortical brain volume and striatal dopamine D2/3 receptor availability in healthy humans assessed with [11 C]-raclopride and [11 C]-(+)-PHNO PET.

Authors:  Fernando Caravaggio; Jun Ku Chung; Eric Plitman; Isabelle Boileau; Philip Gerretsen; Julia Kim; Yusuke Iwata; Raihaan Patel; M Mallar Chakravarty; Gary Remington; Ariel Graff-Guerrero
Journal:  Hum Brain Mapp       Date:  2017-07-28       Impact factor: 5.038

2.  Preclinical Evaluation of the First Adenosine A1 Receptor Partial Agonist Radioligand for Positron Emission Tomography Imaging.

Authors:  Min Guo; Zhan-Guo Gao; Ryan Tyler; Tyler Stodden; Yang Li; Joseph Ramsey; Wen-Jing Zhao; Gene-Jack Wang; Corinde E Wiers; Joanna S Fowler; Kenner C Rice; Kenneth A Jacobson; Sung Won Kim; Nora D Volkow
Journal:  J Med Chem       Date:  2018-11-13       Impact factor: 7.446

3.  Baseline reward processing and ventrostriatal dopamine function are associated with pramipexole response in depression.

Authors:  Alexis E Whitton; Jenna M Reinen; Mark Slifstein; Yuen-Siang Ang; Patrick J McGrath; Dan V Iosifescu; Anissa Abi-Dargham; Diego A Pizzagalli; Franklin R Schneier
Journal:  Brain       Date:  2020-02-01       Impact factor: 13.501

4.  Dopamine Release in Antidepressant-Naive Major Depressive Disorder: A Multimodal [11C]-(+)-PHNO Positron Emission Tomography and Functional Magnetic Resonance Imaging Study.

Authors:  Franklin R Schneier; Mark Slifstein; Alexis E Whitton; Diego A Pizzagalli; Jenna Reinen; Patrick J McGrath; Dan V Iosifescu; Anissa Abi-Dargham
Journal:  Biol Psychiatry       Date:  2018-05-25       Impact factor: 13.382

Review 5.  Potential Mechanisms for Why Not All Antipsychotics Are Able to Occupy Dopamine D3 Receptors in the Brain in vivo.

Authors:  Béla Kiss; Balázs Krámos; István Laszlovszky
Journal:  Front Psychiatry       Date:  2022-03-24       Impact factor: 4.157

6.  Motor Synchronization to Rhythmic Auditory Stimulation (RAS) Attenuates Dopaminergic Responses in Ventral Striatum in Young Healthy Adults: [11C]-(+)-PHNO PET Study.

Authors:  Yuko Koshimori; Antonio P Strafella; Mikaeel Valli; Vivek Sharma; Sang-Soo Cho; Sylvain Houle; Michael H Thaut
Journal:  Front Neurosci       Date:  2019-02-14       Impact factor: 4.677

7.  Variability in Action Selection Relates to Striatal Dopamine 2/3 Receptor Availability in Humans: A PET Neuroimaging Study Using Reinforcement Learning and Active Inference Models.

Authors:  Rick A Adams; Michael Moutoussis; Matthew M Nour; Tarik Dahoun; Declan Lewis; Benjamin Illingworth; Mattia Veronese; Christoph Mathys; Lieke de Boer; Marc Guitart-Masip; Karl J Friston; Oliver D Howes; Jonathan P Roiser
Journal:  Cereb Cortex       Date:  2020-05-18       Impact factor: 5.357

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.